Analyst Price Targets — VRPX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 19, 2024 7:54 am | Naz Rahman | Maxim Group | $3.00 | $1.70 | StreetInsider | Maxim Group Upgrades Virpax Pharmaceuticals, Inc. (VRPX) to Buy |
Latest News for VRPX
Volatility and Risk Virpax Pharmaceuticals has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500. Comparatively, Zomedica has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Profitability This table compares Virpax Pharmaceuticals and Zomedica's net margins, return on
Risk and Volatility Virpax Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, Merck KGaA has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Insider and Institutional Ownership 32.2% of Virpax Pharmaceuticals shares are held
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VRPX.
U.S. House Trading
No House trades found for VRPX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.